Immunodiffusion assay of C1 inhibitor function in serum: prospective analysis in angioedema-urticaria.

An immunodiffusion assay for detecting C1 inhibitor function in human serum was described recently by Ziccardi and Cooper. In our present study, the applicability of this assay for C1 inhibitor deficiency or C1 inhibitor dysfunction was evaluated. Of the 39 patients evaluated, all eight patients with the common (C1 inhibitor deficiency) form of hereditary angioedema and all three patients with the variant (dysfunctional C1 inhibitor) form of hereditary angioedema were identified correctly. Treatment of patients with hereditary angioedema with stanozolol or danocrine increased their serum C1 inhibitor concentrations and normalized the immunodiffusion assay for C1 inhibitor function. In addition, the assay allowed the correct identification of three patients with the acquired form of C1 inhibitor deficiency, because the sera of these patients exhibited a distinctive pattern. The 25 samples from patients (chronic angioedema, chronic urticaria, or hypocomplementemic vasculitis) without C1 inhibitor deficiency had normal assays.

[1]  A. Sheffer,et al.  Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.

[2]  N. Cooper,et al.  Development of an immunochemical test to assess C1 inactivator function in human serum and its use for the diagnosis of hereditary angioedema. , 1980, Clinical immunology and immunopathology.

[3]  G. Boss,et al.  Acquired C1 Esterase Inhibitor Deficiency and Angioedema: A Review , 1979, Medicine.

[4]  Robert B Sim,et al.  A simplified procedure for the purification of C1̄‐inactivator from human plasma Interaction with complement subcomponents C1̄r and C1̄s , 1977, FEBS letters.

[5]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[6]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.

[7]  N. Cooper,et al.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. , 1975, The Journal of clinical investigation.

[8]  R. Stroud,et al.  C1r deficiency: an inborn error associated with cutaneous and renal disease. , 1972, The Journal of clinical investigation.

[9]  C. Forbes,et al.  Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. , 1970, The Journal of laboratory and clinical medicine.

[10]  R. Colman,et al.  Interaction of plasma kallikrein with the C1 inhibitor. , 1970, Journal of immunology.

[11]  O. Ratnoff,et al.  THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR , 1969, The Journal of experimental medicine.

[12]  D. M. Weir,et al.  Handbook of experimental immunology , 1967 .

[13]  F. Rosen,et al.  Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.